File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Liposome-encapsulated 0.5% 5-aminolevulinic acid with intense pulsed light for the treatment of inflammatory facial acne: A pilot study

TitleLiposome-encapsulated 0.5% 5-aminolevulinic acid with intense pulsed light for the treatment of inflammatory facial acne: A pilot study
Authors
Issue Date2011
Citation
Dermatologic Surgery, 2011, v. 37 n. 4, p. 450-459 How to Cite?
AbstractBackground: Liposome used in spray form to encapsulate and deliver 5-aminolevulinic acid (5-ALA) into the pilosebaceous unit lowers the concentration of 5-ALA to 0.5% in photodynamic therapy (PDT) for acne, with low post-treatment photosensitivity. Objective: To investigate the clinical outcome and side effects of PDT using intense pulsed light (IPL) and 0.5% 5-ALA spray for inflammatory facial acne in Asian skin. Methods: Twelve subjects (skin types IV-V) with facial acne received full-face treatment at 3-week intervals with IPL 1 hour after being sprayed with 5-ALA. Lesion counts were assessed using serial standardized photographs taken up to 6 months after treatment. Serial sebum measurement and subjective assessment was conducted. Results: There were mean reductions in inflammatory lesions of 52% at 1 month (p=.02) and 65% at 6 months (p=.04) after treatment. Mean subjective acne score decreased from 6.6 to 4.5 (on a scale from 1 to 10) 1 month after treatment. Significant reduction in sebum production was noted only on the forehead. No significant side effects, including postinflammatory hyperpigmentation and phototoxicity, were observed. Conclusion: Use of 0.5% liposome-encapsulated 5-ALA spray with IPL reduced inflammatory facial acne in Asians, with a low risk of persistent phototoxic effects after PDT in this pilot study. Danish Dermatologic Development, HÃrsholm, Denmark provided the IPL device and liposome-encapsulated 5-ALA spray used in this study. © 2011 by the American Society for Dermatologic Surgery, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/176311
ISSN
2015 Impact Factor: 1.936
2015 SCImago Journal Rankings: 1.084
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYeung, CKen_US
dc.contributor.authorShek, SYen_US
dc.contributor.authorYu, CSen_US
dc.contributor.authorKono, Ten_US
dc.contributor.authorChan, HHen_US
dc.date.accessioned2012-11-26T09:08:56Z-
dc.date.available2012-11-26T09:08:56Z-
dc.date.issued2011en_US
dc.identifier.citationDermatologic Surgery, 2011, v. 37 n. 4, p. 450-459en_US
dc.identifier.issn1076-0512en_US
dc.identifier.urihttp://hdl.handle.net/10722/176311-
dc.description.abstractBackground: Liposome used in spray form to encapsulate and deliver 5-aminolevulinic acid (5-ALA) into the pilosebaceous unit lowers the concentration of 5-ALA to 0.5% in photodynamic therapy (PDT) for acne, with low post-treatment photosensitivity. Objective: To investigate the clinical outcome and side effects of PDT using intense pulsed light (IPL) and 0.5% 5-ALA spray for inflammatory facial acne in Asian skin. Methods: Twelve subjects (skin types IV-V) with facial acne received full-face treatment at 3-week intervals with IPL 1 hour after being sprayed with 5-ALA. Lesion counts were assessed using serial standardized photographs taken up to 6 months after treatment. Serial sebum measurement and subjective assessment was conducted. Results: There were mean reductions in inflammatory lesions of 52% at 1 month (p=.02) and 65% at 6 months (p=.04) after treatment. Mean subjective acne score decreased from 6.6 to 4.5 (on a scale from 1 to 10) 1 month after treatment. Significant reduction in sebum production was noted only on the forehead. No significant side effects, including postinflammatory hyperpigmentation and phototoxicity, were observed. Conclusion: Use of 0.5% liposome-encapsulated 5-ALA spray with IPL reduced inflammatory facial acne in Asians, with a low risk of persistent phototoxic effects after PDT in this pilot study. Danish Dermatologic Development, HÃrsholm, Denmark provided the IPL device and liposome-encapsulated 5-ALA spray used in this study. © 2011 by the American Society for Dermatologic Surgery, Inc.en_US
dc.languageengen_US
dc.relation.ispartofDermatologic Surgeryen_US
dc.subject.meshAcne Vulgaris - Drug Therapyen_US
dc.subject.meshAdulten_US
dc.subject.meshAminolevulinic Acid - Administration & Dosageen_US
dc.subject.meshAsian Continental Ancestry Groupen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshHumansen_US
dc.subject.meshLiposomesen_US
dc.subject.meshMaleen_US
dc.subject.meshPhotochemotherapy - Methodsen_US
dc.subject.meshPhotosensitizing Agents - Administration & Dosageen_US
dc.subject.meshPilot Projectsen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshYoung Adulten_US
dc.titleLiposome-encapsulated 0.5% 5-aminolevulinic acid with intense pulsed light for the treatment of inflammatory facial acne: A pilot studyen_US
dc.typeArticleen_US
dc.identifier.emailYu, CS: carolsyu@hku.hken_US
dc.identifier.authorityYu, CS=rp00305en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1524-4725.2011.01929.xen_US
dc.identifier.pmid21414073-
dc.identifier.scopuseid_2-s2.0-79954533710en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79954533710&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume37en_US
dc.identifier.issue4en_US
dc.identifier.spage450en_US
dc.identifier.epage459en_US
dc.identifier.isiWOS:000289155400007-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridYeung, CK=7201354123en_US
dc.identifier.scopusauthoridShek, SY=35995822400en_US
dc.identifier.scopusauthoridYu, CS=8856262400en_US
dc.identifier.scopusauthoridKono, T=26643566000en_US
dc.identifier.scopusauthoridChan, HH=24555248900en_US
dc.identifier.citeulike9114658-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats